International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F20%3AA21027JB" target="_blank" >RIV/61988987:17110/20:A21027JB - isvavai.cz</a>
Alternative codes found
RIV/00843989:_____/20:E0108613
Result on the web
<a href="https://www.nature.com/articles/s41408-020-00366-3" target="_blank" >https://www.nature.com/articles/s41408-020-00366-3</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/s41408-020-00366-3" target="_blank" >10.1038/s41408-020-00366-3</a>
Alternative languages
Result language
angličtina
Original language name
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
Original language description
Smoldering multiple myeloma (SMM) is an asymptomatic precursor state of multiple myeloma (MM). Recently, MM was redefined to include biomarkers predicting a high risk of progression from SMM, thus necessitating a redefinition of SMM and its risk stratification. We assembled a large cohort of SMM patients meeting the revised IMWG criteria to develop a new risk stratification system. We included 1996 patients, and using stepwise selection and multivariable analysis, we identified three independent factors predicting progression risk at 2 years: serum M-protein >2 g/dL (HR: 2.1), involved to uninvolved free light-chain ratio >20 (HR: 2.7), and marrow plasma cell infiltration >20% (HR: 2.4). This translates into 3 categories with increasing 2-year progression risk: 6% for low risk (38%; no risk factors, HR: 1); 18% for intermediate risk (33%; 1 factor; HR: 3.0), and 44% for high risk (29%; 2-3 factors). Addition of cytogenetic abnormalities (t(4;14), t(14;16), +1q, and/or del13q) allowed separation into 4 groups (low risk with 0, low intermediate risk with 1, intermediate risk with 2, and high risk with >= 3 risk factors) with 6, 23, 46, and 63% risk of progression in 2 years, respectively. The 2/20/20 risk stratification model can be easily implemented to identify high-risk SMM for clinical research and routine practice and will be widely applicable.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Blood Cancer Journal
ISSN
2044-5385
e-ISSN
—
Volume of the periodical
10
Issue of the periodical within the volume
10
Country of publishing house
GB - UNITED KINGDOM
Number of pages
11
Pages from-to
—
UT code for WoS article
000578090500001
EID of the result in the Scopus database
—